Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Healthy, HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Trametinib; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Leukemia, Solid Tumors
Interventions: Clinimacs Cell Separation System, conditioning chemotherapy, DLI; Device · Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 6 Months to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes; Drug · Biological · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK0803, Excipient; Biological · Other
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions: romidepsin, lenalidomide, laboratory biomarker analysis; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 16 more

Conditions: Graft vs Host Disease
Interventions: Begelomab, Conventional Second-line Treatment; Biological
Lead sponsor: Adienne SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more

Conditions: Small Cell Lung Cancer
Interventions: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate; Biological · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions: 50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Influenza
Interventions: Fluzone® (intramuscular), FluMist® (intranasal); Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 100 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2043
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lymphoma
Interventions: Alefacept; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 3
States / cities: Duarte, California • Iowa City, Iowa • Rochester, Minnesota

Conditions: Dermatomyositis
Interventions: KYV-101; Biological
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 72 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Epcoritamab, Rituximab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Cervical Intraepithelial Neoplasia
Interventions: E7 TCR; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions: Home Automated Telemanagement (HAT) Patient Unit; Device
Lead sponsor: University of Utah; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Peripheral T-cell Lymphoma
Interventions: Not listed
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 68
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 54 more

Conditions: Psoriasis
Interventions: risankizumab; Drug
Lead sponsor: Oregon Medical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Wheat Bioactives and Immune Function

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

Epcoritamab and Rituximab for First-line Follicular Lymphoma

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

High Dose Risankizumab for Psoriasis